Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Sarcoma 3 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Urinary Bladder Neoplasms 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liposarcoma 1 Leiomyosarcoma 1 Inoperable Locally Advanced HER2-Negative Breast Cancer 1 Inflammatory Breast Neoplasms 1 HR Positive HER2 Negative Advanced Breast Cancer 1 HER-2 Positive Breast Cancer 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Carcinoma 1 Brain Neoplasms 1 Advanced Breast Cancer 1

Interventions

Temozolomide 26 Bevacizumab 14 Radiosurgery 12 Radiotherapy 9 pembrolizumab 8 Carboplatin 8 Trastuzumab 6 temsirolimus 5 Sirolimus 5 Erlotinib Hydrochloride 5 abemaciclib 4 Paclitaxel 4 Irinotecan 4 Capecitabine 4 tipifarnib 3 Sorafenib 3 Radiation 3 Mental Status and Dementia Tests 3 Ipilimumab 3 Everolimus 3 Aminolevulinic Acid 3 130-nm albumin-bound paclitaxel 3 tucatinib 2 pertuzumab 2 fludarabine 2 durvalumab 2 alovudine 2 alectinib 2 Vorinostat 2 Surgical Procedures, Operative 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Brain Neoplasms × eribulin × Clear all

NCT04711824 2025-12-23

SOLARA

Hoosier Cancer Research Network

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡